PubMed Health⌕ Search

Biomedical subjects

H Welters

Publications and source records attributed to H Welters.

5 recordsLinked to original sources
PubMed2002

One-stage bilateral total hip replacement: a retrospective study of 70 patients.

In this study, we retrospectively reviewed 70 patients who had a one-stage bilateral total hip replacement in our institution, between 1992 and 1998. Different variables were considered such as gender, age, length of hospital stay, pre-operative diagnosis, duration of the operation and anesthesia, type of prosthesis, complications and amount of blood loss, pre- and postoperative range of motion, incidence of periarticular heterotopic ossifications and postoperative pain and walking distance. In our group of patients one-stage bilateral total hip replacement was found to have resulted in good objective results. Patients with a rheumatoid condition had the highest gain in postoperative hip mobility. In comparison with existing literature there were no more intra- or postoperative complications, making one-stage bilateral total hip replacement a safe procedure in well-selected cases.

Adolescent↗
PubMed1990

A modified cytotoxicity assay with high sensitivity.

Since adoptive immunotherapy using lymphokine activated killer (LAK) cells and interleukin-2 (IL-2) has been introduced into clinical medicine, there has been a growing interest in cytotoxicity assays. The standard 51chromium release assay has certain disadvantages, in particular limited sensitivity, because of a high, nonspecific background release. We examined the conditions under which tritiated thymidine, which has been used to assess slow macrophage mediated cytolysis, can be utilized to assess the rapid cytotoxic activity of unstimulated PBL and LAK cells. The optimal assay duration for the 3H-thymidine (3H-TdR) release assay is 24 h. Under standard conditions actively proliferating effector cells do incorporate some of the 3H-TdR released by the target cells during this time, leading to false low results. This problem can be abolished by the addition of excessive amounts of cold TdR to the assay medium. We found a good correlation of the results of the TdR release assay and the Cr release assay. Using the very sensitive TdR release assay, unexpected significant cytolysis of the so-called 'NK resistant' Daudi cells by unstimulated PBL is demonstrated. The modified 3H-TdR release assay is well-suited to monitor the immunological effects of immunotherapy, using IL-2 and LAK cells.

Chromium Radioisotopes↗
PubMed1990

[Interleukin 2: immunologic background and clinical use in tumor therapy].

The cytokine interleukin 2 (IL 2) has proved to be an effective agent in immunotherapy of human cancers. Natural killer cells and cytotoxic T-lymphocytes are activated via membrane receptors by IL 2. IL 2-activated natural killer cells and cytotoxic T-lymphocytes develop high cytolytic activity against a variety of tumor cells in vitro. After extensive animal experiments, IL 2 was used in humans either alone or in combination with lymphokine-activated killer cells or tumor-infiltrating lymphocytes. Its application in humans is still experimental, although initial results are very promising. Further studies are necessary to establish treatment protocols with high therapeutic efficacy and tolerable side effects.

Animals↗
PubMed1988

[A new approach in the treatment of metastatic melanoma: adoptive immunotherapy using lymphokine-activated killer cells and interleukin 2].

The treatment of metastatic malignant melanoma remains unsatisfactory. Recently, immunological approaches have been examined. In this respect, therapy with interleukin 2 (Il 2) and Lymphokine-activated killer cells (LAK-cells) is of special interest. In the present paper, the results from the literature are reviewed, and the first patient is reported, who was treated in our department with this therapeutic regimen in a phase-one study to examine the toxicity of a new Il 2 preparation.

Humans↗